Noxafil

Noxafil is a brand name of posaconazole, approved by the FDA in the following formulation(s):

NOXAFIL (posaconazole - suspension; oral)

• 
  Manufacturer: SCHERING
  
  Approval date: September 15, 2006
  
  Strength(s): 40MG/ML ^[RLD]

Has a generic version of Noxafil been approved?

No. There is currently no therapeutically equivalent version of Noxafil available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Noxafil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tetrahydrofuran antifungals
  Patent 5,661,151
  Issued: August 26, 1997
  Inventor(s): Saksena; Anil K. & Girijavallabhan; Viyyoor M. & Lovey; Raymond G. & Pike; Russell E. & Wang; Haiyan & Liu; Yi-Tsung & Ganguly; Ashit K. & Bennett; Frank
  Assignee(s): Schering Corporation
  A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two hydroxy moieties, an ether or ester thereof (e.g., a polyether ester amino acid ester or phosphate ester) thereof or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
  
  Patent expiration dates:
  
  
  • July 19, 2019
    
    ✓ 
    Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Tetrahydrofuran antifungals
  Patent 5,703,079
  Issued: December 30, 1997
  Inventor(s): Saksena; Anil K. & Girijavallabhan; Viyyoor M. & Lovey; Raymond G. & Pike; Russell E. & Wang; Haiyan & Liu; Yi-Tsung & Ganguly; Ashit K. & Bennett; Frank
  Assignee(s): Schering Corporation
  A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two polyetyher ester groups (e.g., a polyether ester convertible in vivo into a hydroxy group) thereof or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
  
  Patent expiration dates:
  
  
  • August 26, 2014
    
    ✓ 
    Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystalline antifungal polymorph
  Patent 6,958,337
  Issued: October 25, 2005
  Inventor(s): Andrews; David R. & Leong; William & Sudhakar; Anantha
  Assignee(s): Schering Corporation
  The crystalline polymorph Form I of (−)-4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by the formula I pharmaceutical compositions containing such a polymorph and methods of using such a polymorph to treat fungal infections in mammals are disclosed.
  
  Patent expiration dates:
  
  
  • October 5, 2018
    
    ✓ 
    Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 15, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Noxafil Consumer Information (Drugs.com)
• Noxafil Suspension Consumer Information (Wolters Kluwer)
• Noxafil Consumer Information (Cerner Multum)
• Noxafil Advanced Consumer Information (Micromedex)
• Noxafil AHFS DI Monographs (ASHP)
• Posaconazole Suspension Consumer Information (Wolters Kluwer)
• Posaconazole Consumer Information (Cerner Multum)
• Posaconazole Advanced Consumer Information (Micromedex)
• Posaconazole AHFS DI Monographs (ASHP)